Share on StockTwits

Acorda Therapeutics (NASDAQ:ACOR) has received an average rating of “Hold” from the eight analysts that are currently covering the company, reports. Five equities research analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $35.90.

Acorda Therapeutics (NASDAQ:ACOR) opened at 30.29 on Tuesday. Acorda Therapeutics has a 52-week low of $27.51 and a 52-week high of $39.95. The stock has a 50-day moving average of $31.27 and a 200-day moving average of $33.56. The company has a market cap of $1.243 billion and a price-to-earnings ratio of 66.09.

Acorda Therapeutics (NASDAQ:ACOR) last issued its quarterly earnings data on Thursday, July 31st. The company reported $0.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.15 by $0.27. The company had revenue of $97.13 million for the quarter, compared to the consensus estimate of $91.40 million. During the same quarter in the previous year, the company posted $0.34 earnings per share. The company’s revenue for the quarter was up 11.5% on a year-over-year basis. On average, analysts predict that Acorda Therapeutics will post $0.22 earnings per share for the current fiscal year.

Separately, analysts at Zacks reiterated a “neutral” rating on shares of Acorda Therapeutics in a research note on Monday, August 4th. They now have a $30.00 price target on the stock.

Acorda Therapeutics, Inc (NASDAQ:ACOR) is a commercial-stage biopharmaceutical company.

Receive News & Ratings for Acorda Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.